Suppression of nuclear factor kappa B ameliorates astrogliosis but not amyloid burden in APPswe/PS1dE9 mice

Neuroscience

Volumn 161, Issue 1, 2009, Pages 53-58

  Zhang, X ^a   Luhrs, K J ^a   Ryff, K A ^a   Malik, W T ^a   Driscoll, M J ^a   Culver, B ^a  

^a UNIVERSITY OF WYOMING   (United States)

Author keywords

Alzheimer's disease; APPswe PS1dE9 mice; astrogliosis; beta amyloid; neuroinflammation; NF B

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CYCLOOXYGENASE 2; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICROTUBULE ASSOCIATED PROTEIN 2; PYRROLIDINE DITHIOCARBAMATE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; ASTROCYTOSIS; CONTROLLED STUDY; DRUG EFFECT; ENCEPHALITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; UPREGULATION;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ASTROCYTES; CEREBRAL CORTEX; CYCLOOXYGENASE 2; HIPPOCAMPUS; INJECTIONS, INTRAPERITONEAL; MICE; MICE, TRANSGENIC; MICROTUBULE-ASSOCIATED PROTEINS; MUTATION; NF-KAPPA B; PROTEIN PRECURSORS; PYRROLIDINES; THIOCARBAMATES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67349092442     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2009.03.010     Document Type: Article

References (28)

1. Aarli J.A. Role of cytokines in neurological disorders. Curr Med Chem 10 (2003) 1931-1937
2. Ahtoniemi T., Goldsteins G., Keksa-Goldsteine V., Malm T., Kanninen K., Salminen A., and Koistinaho J. Pyrrolidine dithiocarbamate inhibits induction of immunoproteasome and decreases survival in a rat model of amyotrophic lateral sclerosis. Mol Pharmacol 71 (2007) 30-37
3. Blasko I., Marx F., Steiner E., Hartmann T., and Grubeck-Loebenstein B. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J 13 (1999) 63-68
4. Bonaiuto C., McDonald P.P., Rossi F., and Cassatella M.A. Activation of nuclear factor-kappa B by beta-amyloid peptides and interferon-gamma in murine microglia. J Neuroimmunol 77 (1997) 51-56
5. Cacquevel M., Lebeurrier N., Cheenne S., and Vivien D. Cytokines in neuroinflammation and Alzheimer's disease. Curr Drug Targets 5 (2004) 529-534
6. Cheng G., Whitehead S.N., Hachinski V., and Cechetto D.F. Effects of pyrrolidine dithiocarbamate on beta-amyloid (25-35)-induced inflammatory responses and memory deficits in the rat. Neurobiol Dis 23 (2006) 140-151
7. Cuzzocrea S., Chatterjee P.K., Mazzon E., Dugo L., Serraino I., Britti D., Mazzullo G., Caputi A.P., and Thiemermann C. Pyrrolidine dithiocarbamate attenuates the development of acute and chronic inflammation. Br J Pharmacol 135 (2002) 496-510
8. Du Y., Chen X., Wei X., Bales K.R., Berg D.T., Paul S.M., Farlow M.R., Maloney B., Ge Y.W., and Lahiri D.K. NF-(kappa)B mediates amyloid beta peptide-stimulated activity of the human apolipoprotein E gene promoter in human astroglial cells. Brain Res Mol Brain Res 136 (2005) 177-188
9. Eikelenboom P., Veerhuis R., Scheper W., Rozemuller A.J., van Gool W.A., and Hoozemans J.J. The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm 113 (2006) 1685-1695
10. Findeis M.A. The role of amyloid beta peptide 42 in Alzheimer's disease. Pharmacol Ther 116 (2007) 266-286
11. Ho G.J., Drego R., Hakimian E., and Masliah E. Mechanisms of cell signaling and inflammation in Alzheimer's disease. Curr Drug Targets Inflamm Allerg 4 (2005) 247-256
12. Hoozemans J.J., Rozemuller J.M., van Haastert E.S., Veerhuis R., and Eikelenboom P. Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology 1. Curr Pharm Des 14 (2008) 1419-1427
13. Iwata M., Muneoka K.T., Shirayama Y., Yamamoto A., and Kawahara R. A study of a dendritic marker, microtubule-associated protein 2 (MAP-2), in rats neonatally treated neurosteroids, pregnenolone and dehydroepiandrosterone (DHEA). Neurosci Lett 386 (2005) 145-149
14. Kaltschmidt B., Uherek M., Volk B., Baeuerle P.A., and Kaltschmidt C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci U S A 94 (1997) 2642-2647
15. Kim W., and Hecht M.H. Sequence determinants of enhanced amyloidogenicity of Alzheimer A{beta}42 peptide relative to A{beta}40 3. J Biol Chem 280 (2005) 35069-35076
16. La Rosa G., Cardali S., Genovese T., Conti A., Di Paola R., La Torre D., Cacciola F., and Cuzzocrea S. Inhibition of the nuclear factor-kappaB activation with pyrrolidine dithiocarbamate attenuating inflammation and oxidative stress after experimental spinal cord trauma in rats. J Neurosurg Spine 1 (2004) 311-321
17. Lucas S.M., Rothwell N.J., and Gibson R.M. The role of inflammation in CNS injury and disease. Br J Pharmacol 147 Suppl 1 (2006) S232-S240
18. Malm T.M., Iivonen H., Goldsteins G., Keksa-Goldsteine V., Ahtoniemi T., Kanninen K., Salminen A., Van Auriola S., Van G.T., Tanila H., and Koistinaho J. Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden. J Neurol Sci 27 (2007) 3712-3721
19. Nurmi A., Lindsberg P.J., Koistinaho M., Zhang W., Juettler E., Karjalainen-Lindsberg M.L., Weih F., Frank N., Schwaninger M., and Koistinaho J. Nuclear factor-kappaB contributes to infarction after permanent focal ischemia. Stroke 35 (2004) 987-991
20. O'Banion M.K. COX-2 and Alzheimer's disease: potential roles in inflammation and neurodegeneration. Expert Opin Investig Drugs 8 (1999) 1521-1536
21. Parvathy S., Davies P., Haroutunian V., Purohit D.P., Davis K.L., Mohs R.C., Park H., Moran T.M., Chan J.Y., and Buxbaum J.D. Correlation between Abetax-40-, Abetax-42-, and Abetax-43-containing amyloid plaques and cognitive decline. Arch Neurol 58 (2001) 2025-2032
22. Patel N.S., Paris D., Mathura V., Quadros A.N., Crawford F.C., and Mullan M.J. Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. J Neuroinflammation 2 (2005) 9
23. Qu B., Boyer P.J., Johnston S.A., Hynan L.S., and Rosenberg R.N. Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. J Neurol Sci 244 (2006) 151-158
24. van Gool W.A., Aisen P.S., and Eikelenboom P. Anti-inflammatory therapy in Alzheimer's disease: is hope still alive?. J Neurol 250 (2003) 788-792
25. von Bernhardi R. Glial cell dysregulation: a new perspective on Alzheimer disease. Neurotox Res 12 (2007) 215-232
26. Wyss-Coray T., Yan F., Lin A.H., Lambris J.D., Alexander J.J., Quigg R.J., and Masliah E. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A 99 (2002) 10837-10842
27. Yamamoto Y., and Gaynor R.B. Role of the NF-kappaB pathway in the pathogenesis of human disease states. Curr Mol Med 1 (2001) 287-296
28. Zhang X., Dong F., Ren J., Driscoll M.J., and Culver B. High dietary fat induces NADPH oxidase-associated oxidative stress and inflammation in rat cerebral cortex. Exp Neurol 191 (2005) 318-325